<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728050</url>
  </required_header>
  <id_info>
    <org_study_id>9510</org_study_id>
    <secondary_id>NCI-2016-00286</secondary_id>
    <secondary_id>9510</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1016000</secondary_id>
    <nct_id>NCT02728050</nct_id>
  </id_info>
  <brief_title>Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome</brief_title>
  <official_title>Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of filgrastim (granulocyte&#xD;
      colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone, when given&#xD;
      together with sorafenib and to see how well they work in treating patients with&#xD;
      newly-diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (likely to be&#xD;
      more aggressive). Drugs used in chemotherapy, such as cladribine, cytarabine, and&#xD;
      mitoxantrone work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells, by stopping them from dividing, or by stopping them from spreading. Colony-stimulating&#xD;
      factors, such as filgrastim, may increase the production of blood cells and may help the&#xD;
      immune system recover from the side effects of chemotherapy. Sorafenib may stop the growth of&#xD;
      cancer cells by blocking some of the enzymes needed for cell growth. Giving filgrastim,&#xD;
      cladribine, cytarabine, and mitoxantrone together with sorafenib may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a phase I, dose-escalation study of mitoxantrone and sorafenib followed by a&#xD;
      phase II study.&#xD;
&#xD;
      INDUCTION: Patients receive mitoxantrone intravenously (IV) over 60 minutes on days 1-3 and&#xD;
      sorafenib orally (PO) twice daily (BID) on days 10-19 in the absence of disease progression&#xD;
      or unacceptable toxicity. Patients also receive filgrastim subcutaneously (SC) once daily&#xD;
      (QD) on days 0-5, cladribine IV QD over 2 hours on days 1-5, and cytarabine IV QD over 2&#xD;
      hours on days 1-5 in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving partial remission (including MRD positive [pos] CR, CR with incomplete platelet&#xD;
      recovery [CRp], and CR with incomplete count recovery [CRi]) or persistent AML may receive up&#xD;
      to 2 cycles of induction therapy per the discretion of the treating physician.&#xD;
&#xD;
      POST-REMISSION: Patients receive sorafenib PO BID on days 8-27 or 3 days prior to next cycle&#xD;
      of treatment, whichever occurs first. Patients also receive filgrastim subcutaneously SC QD&#xD;
      on days 0-5, cladribine IV QD over 2 hours on days 1-5, and cytarabine IV QD over 2 hours on&#xD;
      days 1-5 in the absence of disease progression or unacceptable toxicity. Patients achieving&#xD;
      MRDneg CR may receive up to 4 cycles of post-remission therapy. Patients achieving disease&#xD;
      response (MRDpos CR, CRi/CRp, or persistent disease) may receive up to two induction cycles&#xD;
      and 1 cycle of post-remission therapy with mitoxantrone omitted in cycle 3. If they then&#xD;
      enter MRDneg CR, they can proceed with up to a total of 4 cycles of post-remission therapy.&#xD;
&#xD;
      MAINTENANCE THERAPY: Patients achieving MRDneg CR may receive maintenance therapy of&#xD;
      sorafenib PO BID for up to 1 year.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>Will be defined as the highest dose studied in which the incidence of dose-limiting toxicity is &lt; 33% assuming at least 6 patients have been treated at this dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease negative (MRDneg) complete response (CR) rate (Phase II)</measure>
    <time_frame>56 days (2 cycles of induction chemotherapy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) scores</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. Will be recorded and summarized using descriptive methods including boxplots, histograms, and statistical summary measures (medians, means, standard deviation, N, and proportions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs, obtained by cost records</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be recorded and summarized using descriptive methods including boxplots, histograms, and statistical summary measures (medians, means, standard deviation, N, and proportions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in hospital</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of hospital stays</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in the intensive care unit</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood product transfusions received</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of febrile neutropenia</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days requiring antibiotic use</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the emergency department</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinic visits</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Acute Biphenotypic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>2CDA</other_name>
    <other_name>CdA</other_name>
    <other_name>Cladribina</other_name>
    <other_name>Leustat</other_name>
    <other_name>Leustatin</other_name>
    <other_name>Leustatine</other_name>
    <other_name>RWJ-26251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <other_name>FILGRASTIM, LICENSE HOLDER UNSPECIFIED</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
    <other_name>Nivestym</other_name>
    <other_name>Filgrastim-aafi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <other_name>Dihydroxyanthracenedione</other_name>
    <other_name>Mitozantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sorafenib, G-CLAM)</arm_group_label>
    <other_name>284461-73-0</other_name>
    <other_name>BAY 43-9006</other_name>
    <other_name>Bay-439006</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years, inclusive&#xD;
&#xD;
          -  Newly diagnosed disease with either a diagnosis of &quot;high-risk&quot; MDS (&gt;= 10% blasts in&#xD;
             marrow or blood), high-risk myeloproliferative neoplasm (MPN; &gt;= 10% blasts in blood&#xD;
             or bone marrow), or AML other than acute promyelocytic leukemia (APL) with&#xD;
             t(15;17)(q22;q12) or variants according to the 2008 World Health Organization (WHO)&#xD;
             classification. Patients with biphenotypic AML are eligible; such &quot;high-risk&quot; MDS or&#xD;
             MPN have natural history much closer to AML than to lower risk MDS or MPN and have&#xD;
             responded similarly to &quot;AML-type&quot; therapy.&#xD;
&#xD;
          -  Outside diagnostic material is acceptable as long as peripheral blood and/or bone&#xD;
             marrow slides are reviewed at the study institution by appropriate clinical staff.&#xD;
             Flow cytometric analysis of peripheral blood and/or bone marrow should be performed&#xD;
             according to institutional practice guidelines.&#xD;
&#xD;
          -  Treatment-related mortality (TRM) score =&lt; 13.1 as calculated with simplified model&#xD;
&#xD;
          -  The use of hydroxyurea prior to study registration is allowed. Patients with&#xD;
             symptoms/signs of hyperleukocytosis, white blood cell (WBC) &gt; 100,000/uL, or acute&#xD;
             symptoms can be treated with leukapheresis or may receive up to 2 doses of cytarabine&#xD;
             (up to 500 mg/m^2/dose) prior to study day 0 enrollment&#xD;
&#xD;
          -  Bilirubin =&lt; 2 times institutional upper limit of normal unless elevation is thought&#xD;
             to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed&#xD;
             within 10 days prior to study day 0)&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dL (assessed within 10 days prior to study day 0)&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;= 45%, assessed within 3 months prior to study day&#xD;
             0, e.g. by multi gated acquisition scan (MUGA) scan or echocardiography, or other&#xD;
             appropriate diagnostic modality and no clinical evidence of congestive heart failure&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             beginning at the signing of the consent until at least 3 months after the last dose of&#xD;
             study drug&#xD;
&#xD;
          -  Provide written informed consent (or legal representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not&#xD;
             considered candidate for CML-directed tyrosine kinase inhibitor treatment (excluding&#xD;
             sorafenib)&#xD;
&#xD;
          -  Concomitant illness associated with a likely survival of &lt; 1 year&#xD;
&#xD;
          -  Active systemic fungal, bacterial, viral, or other infection, unless disease is under&#xD;
             treatment with anti-microbials and/or controlled or stable (e.g. if specific,&#xD;
             effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis,&#xD;
             human immunodeficiency virus (HIV)]). Patient needs to be clinically stable as defined&#xD;
             as being afebrile and hemodynamically stable for 24-48 hours prior to study day 0,&#xD;
             unless fever is thought to be secondary to the underlying hematologic disease.&#xD;
&#xD;
          -  Active or clinically significant (or symptomatic) cardiac disease, including active&#xD;
             coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other&#xD;
             than beta blockers or digoxin within the last 3 months, unstable angina (anginal&#xD;
             symptoms at rest), new-onset angina within 3 months before randomization, or&#xD;
             myocardial infarction within 6 months before study day 0&#xD;
&#xD;
          -  Previous receipt of azacitidine, decitabine, anthracyclines, cytarabine, or other&#xD;
             nucleoside analogues for treatment of AML or MPN/MDS other than as noted for&#xD;
             cytarabine&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Concurrent treatment with any other investigational agent that has anti-leukemia&#xD;
             activity or another drug with anti-AML-activity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Halpern</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

